Welcome to our dedicated page for EHAVE ORD news (Ticker: EHVVF), a resource for investors and traders seeking the latest updates and insights on EHAVE ORD stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect EHAVE ORD's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of EHAVE ORD's position in the market.
Ehave, Inc. (OTC Pink: EHVVF) announced the acquisition of Rejuv IV, enhancing its KetaDASH brand. This mobile IV therapy provider, active in the San Francisco Bay Area, offers services such as Ketamine treatments and IV Vitamin Therapy. CEO Ben Kaplan emphasized the company's commitment to mental health, highlighting KetaDASH’s role in providing lifesaving treatments for psychiatric disorders like depression and PTSD. The service combines at-home administration with telehealth supervision, expanding Ehave's reach in mental health therapeutics.
Ehave, Inc. (EHVVF) shares insights in a letter to shareholders from CEO Ben Kaplan, highlighting advancements in digital therapeutics for mental health using psychedelics. The company emphasizes mental health issues affecting millions in the U.S. and aims to enhance treatments. Key developments from 2021 include a strengthened balance sheet and successful product development. With plans to monetize technology through licensing, Ehave anticipates significant growth. Additionally, Ehave will distribute 30% of PSLY.COM holdings to shareholders and targets launching the KetaDASH home delivery service soon.
Ehave has signed a Letter of Intent (LOI) with Ei.Ventures to explore a merger forming PSLY.COM, an estimated $360 million transaction. As part of this process, Ehave plans to spin out 30% of its Mycotopia Therapies shares to existing shareholders. Ehave currently holds approximately 9.8 million shares of Mycotopia, which focuses on psilocybin-based therapeutics. The merged companies aim to list on NASDAQ after completing pre-clinical trials for their flagship product, Psilly. This move is seen as a strategic shift towards enhancing shareholder value and market presence.
Ehave, Inc. (EHVVF) announced its KetaDASH platform will sponsor the 2021 Psychedelic Investor Guide. KetaDASH is an IV-based home delivery service for ketamine therapy aimed at enhancing patient care. CEO Ben Kaplan highlighted the platform's HIPAA compliance and early market entry. The Investor Guide features 46 prominent companies in the psychedelic sector, providing essential investment data, including stock charts and financial information. This comprehensive guide will be updated monthly and aims to simplify research for investors in the rapidly developing psychedelic investment landscape.
Ehave, based in Miami, has initiated a ketamine clinical trial aimed at exploring the potential of ketamine to promote neuroplasticity and address mental health issues. The company has engaged KGK Science Inc. to develop the necessary protocol and Informed Consent Form for its Institutional Review Board application. The trial will involve four ketamine infusions for each patient, with the goal of obtaining objective data to support the treatment's effectiveness for depression and related conditions. Ehave also plans to expand its KetaDASH platform to enhance mental health care.
Ehave, Inc. (OTC Pink: EHVVF) announced on September 30, 2021, that the Psychedelic Stock Review has initiated coverage of the company. Ehave is set to launch a range of digital tools aimed at enhancing the effectiveness of Psychedelic treatments. The company previously sold its Clinical Software Platform for $3.2 million and is transitioning to provide patient reporting services in the Psychedelic sector. Key upcoming products include KetaDash, MegaTeam, and the Ehave Health Records Dashboard, all designed to improve patient monitoring and data collection in the growing market for Psychedelic therapies.
Ehave (OTC Pink: EHVVF), a provider of digital therapeutics for the psychedelic and mental health sectors, announced its inclusion in the 2021 Psychedelic Investor Guide. This guide features leading companies in the emerging psychedelics medicine industry, showcasing Ehave's strategy of integrating digital therapeutics with psychedelic medicine. President Ben Kaplan emphasized that this recognition boosts investor awareness and highlights the company's significant initiatives. The guide aims to familiarize investors with key companies, further validating the potential for success in the psychedelics sector.
Ehave, Inc. (OTC Pink: EHVVF) announced the addition of Dr. Rahul Dixit to its Medical Advisory Board. Dr. Dixit, a Gastroenterology Specialist with over 17 years in the medical field, will advise on human trials for cognitive and psychedelic opportunities and mental health analytical platforms. His expertise in gastrointestinal ailments, particularly those linked to mental health, aligns with Ehave's focus on digital therapeutics for brain disorders. CEO Ben Kaplan expressed confidence in Dr. Dixit's valuable contributions as the company expands its operations.
Ehave, Inc. (EHVVF) announced the upcoming launch of its Covid Passport, aimed at helping small businesses verify Covid-19 vaccinations. This tool will simplify vaccination tracking for employers and provide individuals a secure method to store their vaccination records. The Covid Passport will be free for users, with enterprise pricing to be disclosed later. Additional products, including KetaDash, MegaTeam, and others, are also progressing towards release. CEO Ben Kaplan emphasized the Covid Passport's role in enhancing workplace safety amidst the pandemic.
Ehave, Inc. (OTC Pink: EHVVF) announced the filing of a Form 6-K with the SEC, revealing a Letter of Intent (LOI) to acquire Moksha Digital Software. This strategic move is projected to significantly enhance revenues, escalating from $10.19 million in the first year to approximately $150.42 million by year five. The Form 6-K also outlines fund utilization and a business plan over five years. The full filing can be accessed at the SEC's website.
FAQ
What is the market cap of EHAVE ORD (EHVVF)?
